Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010233

International filing date: 25 March 2005 (25.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/557,740
Filing date: 29 March 2004 (29.03.2004)

Date of receipt at the International Bureau: 09 May 2005 (09.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1314671

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 27, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/557,740*
FILING DATE: *March 29, 2004*
RELATED PCT APPLICATION NUMBER: *PCT/US05/10233*

Certified by

Jon W. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PTO/SB/16 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unless it displays e valid OMB control number.

17707 U.S. PTO 032904
42278 U.S. PTO 60/557740 032904

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Expresse Mell Lebel No. ER 388500347 US

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Robin L.	Polt	Tucson, Arizona

Additional inventors are being named on the 1 *separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

Amphipathic Helical Glycopeptide Address Sequences for Enhanced Blood-Brain Barrier Transport of Neuroactive Peptides

Direct all correspondence to: **CORRESPONDENCE ADDRESS**

☑ Customer Number: 021368

OR

☐ Firm or Individual Name	David G. Perry				
Address	Office of Technology Transfer; The University of Arizona				
Address	888 N. Euclid Ave., Rm. 204; P.O. Box 210158				
City	Tucson	State	AZ	Zip	85721
Country	USA	Telephone	520-621-5000	Fax	520-626-4600

ENCLOSED APPLICATION PARTS *(check all that apply)*

☑ Specification *Number of Pages* 44 ☐ CD(s), Number _____

☐ Drawing(s) *Number of Sheets* _____ ☐ Other (specify) _____

☐ Application Date Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☑ Applicant claims small entity status. See 37 CFR 1.27.

☐ A check or money order is enclosed to cover the filing fees.

☑ The Director is herby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 500884

☐ Payment by credit card. Form PTO-2038 is attached.

FILING FEE Amount ($): 80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☐ No.

☑ Yes, the name of the U.S. Government agency and the Government contract number are: Navy/ONR; N00014-02-1-0471

Respectfully submitted

SIGNATURE David G. Perry

TYPED or PRINTED NAME David G. Perry

TELEPHONE 520-621-5000

Date 3/29/2004

REGISTRATION NO. 34,405 *(if appropriate)*

Docket Number: UA 04-065

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of informetion is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 end 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, end submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the emount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number UA 04-065

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Dhanasekaran	Muthu	Tucson, Arizona

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label No. **ER 388500347 US**

Date of Deposit: March 29, 2004

I hereby certify that this correspondence is
being deposited with the United States Postal
Service as "Express Mail Post Office to Addressee"
service under 37 C.F.R. 1.10 on date indicated
above and such envelope is addressed to Mail Stop Provisional
Patent Application, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450

David G. Perry
(Name of Applicant, assignee or
registered representative)



(Signature)

3/29/04

(Date)

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

U.S. Provisional Patent Application

TITLE: Amphipathic Helical Glycopeptide Address Sequences for Enhanced Blood-Brain Barrier Transport of Neuroactice Peptides

INVENTORS: Robin L. Polt & Dhanasekaran Muthu

FILED: March 29, 2004

Glycopeptide Analgesics: Conformational and Pharmacological Characterization of O-Linked Glycosyl-Enkephalins and Glycosyl-Endorphins

Robin Polt, Dhanasekaran Muthu, Edward J. Bilsky, Henry I. Yamamura, Frank Porreca, Larissa Yeomans, Charles M. Keyari, Richard D. Egleton

Endogenous Opioid Peptides

Tyr-Gly-Gly-Phe-Met

Tyr-Gly-Gly-Phe-Leu

Enkephalins

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu^{31}

beta-Endorphin

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asn-Asn-Gln^{17}

Dynorphin-A

i.v. vs s.c. Injection



1st Generation Helix Design





YtGFLGELAS*-KWFNA-LES*-$CONH_2$



YtGFLGELAS*KWFNALES*-$CONH_2$

1st & 2nd Generation Helical Opioids

Peptide Sequence	*delta* IC_{50} nM	*mu* IC_{50} nM
YtGFLGELAS*KWFNALE-$CONH_2$	insoluble in H_2O	
YtGFLGELAS*KWFNALES*-$CONH_2$	9.5	144
YtGFLGELAS*KWFNALES*F-$CONH_2$	insoluble in H_2O	
YtGFLGELAS*KWFNALES*FW-$CONH_2$	insoluble in H_2O	
YtGFLGALKS*FAES*LS*N-$CONH_2$	—	—
YtGFLGLLKS*FAES*WS*NF-$CONH_2$	11.9	154
YtGFLGKS*FAELWS*NFLS*-$CONH_2$	25.6	38.2
YtGFLGLLKS*FWES*WS*NF-$CONH_2$	—	—

3rd Generation Helix Design



3rd Generation Helices



Dhana Muthu *(unpublished results)*

Octanol:Saline Distribution Studies



Mouse *in situ* Perfusion Studies



K_{in} Values from *in situ* Perfusion Studies



Initial Volume of Distribution (V_d) from *in situ* Perfusion Studies



Functional Bio-Assays

H_2N-Y-t-G-F-L-Linker-N-B-E-K-A-L-K-Ser(Glc)-L-NH_2

Linker	MVD (IC_{50})	GPI (IC_{50})	Ratio (delta/mu)
Pro	34.5 nM	63.1 nM	1.8
beta-Ala	23.0 nM	354 nM	15
Gly-Gly	18.8 nM	196 nM	10
Morphine	258 nM	54.7 nM	0.21

Peg Davis, U. of A. Pharmacology (*unpublished*)

Glycopeptide analgesics: Conformational and pharmacological characterization of O-linked glycosyl-enkephalins and glycosyl-endorphins

Dhanasekaran Muthu Ph.D.
Prof. Robin Polt's Laboratory
Department of Chemistry
The University of Arizona
Tucson 85721

Opioid receptor and their agonist effects



- Analgesia

- Analgesia
- Respiratory depression
- Miosis
- Reduced
  -gastrointestinal motility
- Nausea
- Vomiting
- Euphoria

- Analgesia
- Respiratory depression
- Miosis
- Dysphoria

M.J. Brownstein, *Proc.Natl.Acad.Sci. USA* **90**:5391-5393(1993)

Naturally occurring opioid peptides

Peptide	*Sequence*	*Receptor Subtype*
Met-Enkephalin	YGGFM	μ/δ
Leu-Enkephalin	YGGFL	δ/μ
Dynorphin A	YGGFLRRIRPKLKWNNQ	κ(μ)
Dynorphin B	YGGFLRRQFKVVT	κ(μ,δ)
α-Neoendorphin	YGGFLRKY	κ(μ,δ)
β-Neoendorphin	YGGFLRKYP	κ(μ,δ)
β_h-Endorphin	YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE	μ/δ
Peptide E	YGGFMRRVGRPEWWMDYQKRYGGFL	μ/κ

Linear Leu-enkephalin analog

Tyr-DThr-Gly-Phe-Leu-Thr-OH (DTLET)



δ selective agonist

G.Gacel et. al. J. Med. Chem., 31:1891-1897(1988)

Glycosylated enkephalin analogue

TYR-(D)THR-GLY-PHE-LEU-SER*-NH_2





β-D-Glucose



B-Lactose



β-Maltose



β-Melibiose

R.Polt et. al. *Proc.Natl.Acad.Sci. USA*. 91:7114-7118(1994)
E.J.Bilsky et. al. *J.Med.Chem*. 43:2586-2590(2000)
S.A.Mitchell et al. *J.Org.Chem*. 66:2327-2342(2001)

Advantages of glycosylated opioid peptide analogs

- Highly water soluble
- Increased serum stability
- Blood brain-barrier is not a problem
- Simple metabolites (amino acid and sugar)
- No side-effects shown on mice, yet

R.Polt et. al. *Proc.Natl.Acad.Sci. USA.* 91:7114-7118(1994)
E.J.Bilsky et. al. *J.Med.Chem.* 43:2586-2590(2000)
R.D.Egleton et. al. *J.Pharm.Expt.Ther.* 299:967-972(2001)
R.D.Egleton et. al. *Brain research* 881:37-46(2000)

Design of helical endorphin/dynorphin analogs

Message segment

Address segment

H_2N-Y-(D)T-G-F-L-Linker-N-B-L-E-K-A-L-K-S*-L-NH_2

Designed to be amphipathic helical



Proline



β-Alanine



Gly-Gly



Design of amphipatic helical address segment

N^{7}-L^{8}-B^{9}-E^{10}-K^{11}-A^{12}-L^{13}-K^{14}-$\underline{S(Sugar)^{15}}$-$L^{16}$



- Purely based on amino acid secondary structure propensity and hydrophobic character
- Asn^{7} as helix cap
- Salt bridge between Glu^{10} and Lys^{14} to improve solubility and helix stability
- Unnatural amino acid to Aib^{9} promote helix formation
- Amino acid heterogenity maintained for NMR characterization

Pharmacology: in vitro binding

Enkephalin analogs



Sugar	MVD (δ) IC_{50} nm	GPI (μ) IC_{50} nm	μ / δ selectivity
No sugar	2.723	25.04	9.1
Glucose	1.56	33.83	21.6
Lactose	5.727	34.75	6.1
Melibiose	6.062	63.14	10.4
Morphine	258	54.7	0.212

Peg Davis, Dept of Pharmacology, University of Arizona

Pharmacology: in vitro binding

Endorphin/dynorphin analogs

H_2N-Y-(D)T-G-F-L-Linker-N-B-E-K-A-L-K-<u>Ser(Glc)</u>-L-NH_2

Linker	MVD (δ) IC_{50} nm	GPI (μ) IC_{50} nm	μ / δ selectivity
Pro	34.49	63.14	1.8
βAla	22.95	353.7	15.4
Gly-Gly	18.79	196.4	10.4
Morphine	258	54.7	0.212

Peg Davis, Dept of Pharmacology, University of Arizona

In vivo pharmacology: Analgesics in mice i.c.v.



Ed Bilsky, University of New England, Maine

In vivo pharmacology: Analgesics in mice i.v.



Ed Bilsky, University of New England, Maine

Peptide conformation by Circular Dicroism

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Glc)-L-NH_2



- Peptide is random coil in water
- Adopts helical conformation in TFE and SDS micelle

Peptide conformation by Circular Dicroism

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Lac)-L-NH_2



- Peptide is random coil in water
- Adopts helical conformation in TFE and SDS micelle

Peptide conformation by Circular Dicroism

H2N-Y-(D)T-G-F-L-βAla-N-L-B-E-K-A-L-K-Ser(Glc)-L-NH2



- Peptide is random coil in water
- Adopts helical conformation in TFE and SDS micelle

Peptide conformation by Circular Dicroism

H2N-Y-(D)T-G-F-L-Gly-Gly-N-L-B-E-K-A-L-K-Ser(Glc)-L-NH2



- Peptide is random coil in water
- Adopts helical conformation in TFE and SDS micelle

Peptide structure by ^{1}H-2D NMR: Chemical shift plot

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Glc)-L-NH_2





Peptide conformation by ^{1}H-2D NMR: Chemical shift plot

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Lac)-L-NH_2



Effect of different sugars on peptide conformation

Water



TFE-Water mixture



SDS micelle



Peptide conformation in SDS micelle by ^{1}H-2D NMR

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Glc)-L-NH_2



Peptide conformation in SDS micelle by ^{1}H-2D NMR

H_2N-Y-(D)T-G-F-L-<u>Pro</u>-N-L-B-E-K-A-L-K-<u>Ser(Glc)</u>-L-NH_2







Peptide conformation in SDS micelle by ^{1}H-2D NMR

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Lac)-L-NH_2





Peptide conformation in SDS micelle by ^{1}H-2D NMR

H_2N-Y-(D)T-G-F-L-Pro-N-L-B-E-K-A-L-K-Ser(Lac)-L-NH_2







Mouse in situ perfusion studies

H_2N-Y-(D)T-G-F-L-Linker-N-L-B-E-K-A-L-K-Ser*-L-NH_2



Richard Egleton, Dept. of Pharmacology, University of Arizona

Kinetic values from in situ perfusion studies



Conclusions

- Glycosylation promotes blood brain-barrier penetration irrespective of the length of the peptide
- Peptide with Proline linker is the best among endorphin analogs and is potential candidate for further development
- Sugar type perturbs the conformation of the peptide in amphipathic media

Dihedral angle distribution over 200ps MD analysis





Peptide 100h in sds

Percentage helicity from circular dichroism



Peptide synthesis



Octanol:saline distribution studies

H_2N-Y-(D)T-G-F-L-Linker-N-L-B-E-K-A-L-K-Ser*-L-NH_2



Richard Egleton, Dept. of Pharmacology, University of Arizona